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Abstract
Purpose—Although cross-sectional studies have demonstrated an association between higher
levels of aerobic fitness and improved neurocognitive function, there have been relatively few
interventional studies investigating this relationship, and results have been inconsistent. We assessed
the effects of aerobic exercise on neurocognitive function in a randomized controlled trial of patients
with major depressive disorder (MDD).
Methods—Two-hundred and two sedentary men (n = 49) and women (n = 153), aged 40 yr and
over and who met diagnostic criteria for MDD, were randomly assigned to the following: a)
supervised exercise, b) home-based exercise, c) sertraline, or d) placebo pill. Before and after 4
months of treatment, participants completed measures of: Executive Function (Trail Making Test B-
A difference score, Stroop Color/Word, Ruff 2 & 7 Test, Digit Symbol), Verbal Memory (Logical
Memory, Verbal Paired Associates), and Verbal Fluency/Working Memory (Animal Naming,
Controlled Oral Word Association Test, Digit Span). Multivariate analyses of covariance were
performed to test the effects of treatment on posttreatment neuropsychological test scores, with
baseline neuropsychological test scores, age, education, and change in depression scores entered as
covariates.
Results—The performance of exercise participants was no better than participants receiving
placebo across all neuropsychological tests. Exercise participants performed better than participants
receiving sertraline on tests of executive function but not on tests of verbal memory or verbal fluency/
working memory.
Conclusions—We found little evidence to support the benefits of an aerobic exercise intervention
on neurocognitive performance in patients with MDD.
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In addition to the well-documented medical benefits of physical exercise (62), the value of
exercise for improving mental health also has been increasingly recognized (59). Published
reviews have concluded that exercise interventions are associated with improved psychological
well-being, life satisfaction, and self-efficacy (44) as well as reduced symptoms of anxiety
(51) and depression (5). Among clinically depressed populations, strength training (58) and
aerobic exercise (20) have been associated with reduced depressive symptoms and remission
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of major depressive disorder (MDD). In previous reports from our laboratory, exercise was
shown to be comparable to antidepressant medication in reducing depressive symptoms among
clinically depressed adults (10), and exercise was shown to be associated with lower risk for
relapse in remitted patients (4). Recently, we conducted a randomized controlled trial and
reported that MDD remission rates for exercisers were comparable to participants taking
antidepressant medication and were better than placebo pill control (9).
Studies evaluating the effects of exercise on neurocognitive function have been more
equivocal. Cross-sectional studies have generally shown that aerobically fit individuals have
higher scores on measures of perceptual speed, reasoning, working memory, and executive
function (i.e., the cognitive ability for volition, planning, purposive action, and effective
performance (40)) compared with their sedentary counterparts (35). Despite the paucity of
randomized controlled trials, a recent meta-analysis of exercise studies on older adults
concluded that exercise was associated with improved cognitive performance, particularly on
tasks that assess executive functions (15). However, results from randomized controlled trials
have been inconsistent; some studies have shown improvements in cognition (21,39,54),
whereas others have not (11,14,30,34).
Aerobic fitness is thought to impact neurocognition by altering brain structure and function
(17). In animal studies, aerobic exercise has been associated with increased cortical capillary
supplies, formation of new synaptic connections, and growth of new neurons, particularly in
the hippocampus (38). Mechanisms may include neurochemicals such as brain-derived
neurotrophin factor and insulin-like growth factor (17,38). A recent study provided preliminary
evidence for an exercise-related growth in cerebral blood volume of the human hippocampus,
suggesting that exercise may benefit humans and mice through similar mechanisms (49).
However, a recent meta-regression of cross-sectional and longitudinal exercise studies in
humans found no evidence for an association between improved fitness and improved
neurocognitive function in humans (24).
As part of a larger randomized clinical trial (9), we examined the effects of aerobic exercise
relative to placebo pill and antidepressant medication on neurocognitive function in a sample
of sedentary, clinically depressed, middle-aged and older adults. We hypothesized that exercise
participants would have greater improvement in neuropsychological test performance
compared with participants receiving either antidepressant medication or placebo pill. We
based our hypothesis that exercise, but not medication, would be associated with improved
neurocognitive performance on the belief that such improvement would not be mediated by
changes in depressive symptoms but rather by exercise-induced biologic changes (as described
above). In a previous study conducted by our research team, clinically depressed adults who
underwent aerobic exercise training exhibited greater improvements on the Stroop Interference
Task compared with participants receiving sertraline (37). Thus, we believed that exercise
training would result in improvements in neurocognitive test performance on tasks that tap
more executive functions.
METHOD
Participants
The details of participant recruitment and experimental design are presented elsewhere (9).
Briefly, participants who gave written informed consent for participation in this IRB-approved
study, who had scores of 12 or greater on the Beck Depression Inventory-2 (BDI) (7), and who
met diagnostic criteria for MDD using the Structured Clinical Interview for the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition (2) and the Hamilton Depression
Rating Scale (HAM-D) (29) completed an assessment battery that included measures of
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cardiopulmonary fitness and neurocognitive function. Bipolar disorder, psychotic depression,
and significant cognitive impairment were excluded.
Assessment of neurocognitive function
A neuropsychological test battery was individually administered to all participants by a trained
research technician who was blind to treatment group assignment. The battery was composed
of tests selected for their use in prior studies, availability of normative data, and measurement
of different cognitive domains, especially executive function. Selected tests included the
following:
Animal Naming (40). Participants name as many animals as possible in 60 s. The animal
naming score is the total number of animals named. This test primarily assesses verbal
fluency but is also reflective of executive function and memory.
Controlled Oral Word Association Test (COWAT) (40). Participants generate as many
words as possible that begin with a specific letter in 60 s. This task is repeated three times
with three different letters. This test measures verbal fluency and also draws on executive
function and memory. For the current study, the three letters alternated between “CFL”
and “PRW” to minimize practice effects.
Digit Symbol Subtest from the Wechsler Adult Intelligence Scale—Revised (WAIS-R)
(63). Participants draw symbols that match one of 10 digits copied from a key. One point
is awarded for each correct symbol drawn in 90 s, with a maximum score of 90. This test
measures psychomotor speed and working memory.
Digit Span Subtest from the WAIS-R (64). Digit span consists of two subtests. Digits
forward requires participants to repeat increasingly long strings of verbally presented
numbers. This is a test of short-term memory storage capacity (40). Digits backward
requires participants to repeat digits in reverse order, an added complexity that places
demand on working memory.
Ruff 2 & 7 Test (55). Participants are provided with 20 sets of characters. In 10 sets, the
numbers “2” and “7” are embedded within other numbers. In 10 sets, the numbers “2” and
“7” are embedded within a series of capital letters. Each trial lasts 15 s. Total score equals
the number of targets hit minus errors of omission and commission. This test requires rapid
visual discrimination and intact executive function.
Stroop Color and Word Test—Interference List (61). The Stroop test consists of three lists:
a word list, a color list, and an interference list. The word list requires participants to read
a list of color words as quickly as possible, with the score being the total number of words
read aloud in 45 s. The color list requires participants to name aloud the color of each of
a series of colored bars in 45 s. The interference list consists of a series of color words,
but the words themselves are colored in a different color ink than the color to which they
refer. Participants are required to name the color of the word but not the word itself. This
is considered a test of executive function.
Trail Making Test (TMT) (40). This test was originally part of the Army Individual Test
Battery. In Part A, participants are required to connect a series of 25 numbered dots. In
Part B, participants are required to connect a series of alternating numbered and lettered
dots. The difference between time to complete Part B and Part A (TMT B-A) is considered
a measure of executive function.
Verbal Paired Associates Subtest from the Wechsler Memory Scale (WMS) (64).
Participants are orally presented with eight word pairs. The four word pairs from the “easy”
list are associated (e.g., baby–cries), whereas the four pairs from the “hard” list are not
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(e.g., school–grocery). Participants are then presented with individual words from each
pair and are asked to recall the paired word.
Logical Memory Subtest from the WMS (64). Participants are required to repeat a story
read aloud to them. Immediate recall was scored using a verbatim scoring procedure. This
test measures short-term semantic memory.
Assessment of physical fitness
Graded treadmill exercise testing was conducted before and after treatment. Patients exercised
to exhaustion or standard end points (e.g., >2 mm ST-segment depression, abnormal blood
pressure response, etc.) under continuous electrocardiographic monitoring using the Duke–
Wake Forest protocol in which workloads are increased at a rate of 1 METImin−1 (13). Expired
air was collected by mouthpiece for quantification of minute ventilation, oxygen consumption,
and carbon dioxide production with a Beckman Metabolic Cart (Model 040-301, Fullerton,
CA). Samples were collected at 20-s intervals, and peak values were determined from an
average obtained during the last 60 s.
Interventions
Participants were randomized to one of four treatment groups:
1. Supervised Aerobic Exercise. Participants exercised three times per week for 16
consecutive weeks. They were assigned individual training ranges equivalent to 70–
85% of their HR reserves, which was calculated from the maximum HR achieved
during the initial treadmill test. HR and RPE were recorded three times during each
exercise session by a trained exercise physiologist.
2. Home-Based Aerobic Exercise. Participants received an initial exercise training
session with an exercise physiologist. During this session, participants received an
individualized exercise prescription, with target ranges equivalent to 70–85% of their
HR reserves, as well as guidance regarding how to implement their exercise program.
Participants received two follow-up sessions with an exercise physiologist for the
purposes of adherence promotion and performance correction. Participants monitored
and recorded their HR and RPE during exercise sessions on weekly exercise logs.
3. Sertraline or 4. Placebo Pill. Participants received sertraline (Zoloft), a selective
serotonin-reuptake inhibitor, or placebo pill. Both participants and study staff were
blind as to whether participants received medication or placebo. Participants met with
a staff psychiatrist at study onset and weeks 2, 4, 8, 12, and 16. Treatment was initiated
at 50 mg and titrated until a well-tolerated therapeutic dosage was achieved, up to 200
mg (four pills). Participants in the pill conditions were instructed to refrain from any
regular exercise until the conclusion of the study.
Data analysis
Principal axis factor analysis with an oblique Promax rotation was used to group the
neuropsychological tests into distinct neurocognitive domains for analyses. The factors were
labeled Executive Function (TMT B-A, Stroop Color–Word, Ruff 2 & 7 Test, Digit Symbol),
Verbal Memory (Logical memory, verbal paired associates—easy, verbal paired Associates—
hard), and Verbal Fluency/Working Memory (Animal Naming, COWAT, Digits Forward,
Digits Backward). Factor loadings can be found in Table 1.
Our primary analyses compared neurocognitive outcomes by treatment group. Three separate
MANCOVA were performed, one for each neurocognitive domain, entering baseline
neuropsychological test scores, education, age, and change in depression (baseline HAM-D
minus posttreatment HAM-D) as covariates. Treatment condition served as the grouping
Hoffman et al. Page 4
Med Sci Sports Exerc. Author manuscript; available in PMC 2009 September 17.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
variable. Because we had no a priori reason to believe that home-based and supervised exercise
would differentially impact neurocognitive function, the supervised and the home-based
exercise conditions were combined into a single exercise group. Unlike placebo, sertraline has
direct central nervous system effects that affect neurocognitive function, so the pill groups
were not combined. Significant univariate treatment effects were examined with planned
contrasts (i.e., exercise vs placebo; exercise vs sertraline). Our primary data analyses used the
intent-to-treat principle; the last observation was carried forward for 23 participants who were
missing posttreatment data.
To further examine the impact of exercise, we also conducted two sets of exploratory analyses
using restricted data sets. We performed a treatment completers analysis, in which the three
MANCOVA were repeated using a data set restricted to those participants who did not formally
withdraw from the study or informally discontinue their treatment regimen and who completed
posttreatment testing. We also performed an optimal exercisers analysis, in which we compared
those exercise participants in the top tertile of improvement in aerobic fitness (i.e., the largest
percent improvement in peak V̇O2 after exercise) with those patients receiving placebo.
All analyses were performed with SAS v 9.1 (56).
RESULTS
Sample Characteristics
The sample consisted of 202 participants (age mean = 51.7 yr; SD = 7.6), the majority of whom
were female (76%) and Caucasian (68%). The sample had an average of 15.8 yr of education
(SD = 2.7). After 4 months of treatment, participants in all treatment groups experienced
decreased symptoms of depression as measured by the HAM-D and the BDI, and participants
receiving active treatments tended to have higher remission rates than placebo controls. Results
of the primary analyses concerning the effects of exercise on depression are reported elsewhere
(9). Sample characteristics by group can be found in Table 2.
Treatment Adherence
One hundred and four participants were randomized to an exercise condition, whereas 49 were
randomized to the sertraline condition and 49 were randomized to the placebo condition.
Among exercise participants, 13 (13%) formally withdrew from the study, and another 8 (8%)
remained in the study but discontinued exercise treatment. Treatment completers attended an
average of 38.8 exercise sessions.
Adherence to medication treatment was evaluated by pill count. The mean maximum dose of
medication prescribed over the course of the study was similar for the sertraline and the placebo
groups (mean = 131 mg for the sertraline group and 133 mg for the placebo group). There were
7 dropouts (14%) in the sertraline condition and 14 dropouts (29%) in the placebo condition.
Effects of Treatment on Aerobic Capacity
Participants in the exercise groups displayed higher levels of aerobic capacity (peak V̇O2) and
greater treadmill times compared with participants who received pills (P’s < 0.0001).
Differences in aerobic capacity and treadmill endurance also were noted between exercise
treatment conditions, with supervised exercise participants achieving higher levels of aerobic
capacity and longer treadmill times than those participants who exercised at home (P’s <
0.0001). The participants in home-based exercise showed an improvement of 3.5% on peak
V ̇O2 and 7.5% on treadmill time; the supervised exercise improved by 8% on peak VO2 and
19% on treadmill time; the sertraline group showed a 1% decrease in peak V̇O2 and 4%
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improvement in treadmill time; and the placebo group declined by 4% on peak V̇O2 and 2%
on treadmill time (see Table 3).
Effects of Treatment on Neurocognitive Function
Pretreatment and posttreatment neurocognitive test scores by treatment group are presented in
Table 4. Mean neuropsychological test values for each treatment group are well within normal
limits (i.e., + 1 SD), both before and after treatment, as compared with demographically
adjusted normative data (19,26,32,55,63,64). These data suggest that the present sample is
reasonably representative of the general population.
The MANCOVA comparing measures of Executive Function revealed a significant treatment
main effect (P = 0.014). Examination of the univariate ANCOVA revealed significant
treatment main effects for TMT B-A (P = 0.046) and Ruff Total Score (P = 0.005), and a
marginally significant treatment main effect for Digit Symbol (P = 0.089). Examination of the
simple contrasts revealed that exercisers had better scores compared with participants in the
sertraline group on TMT B-A (P = 0.02), Ruff total score (P = 0.002), and digit symbol (P =
0.03). Simple contrasts between exercisers and placebo group participants were not significant.
Neither the MANCOVA comparing memory scores by treatment group nor the MANCOVA
comparing verbal fluency/working memory scores by treatment group were significant.
Treatment completers analysis—The three MANCOVA were repeated using only
available data from treatment completers (exercisers, n = 82; sertraline, n = 41; and placebo,
n = 35). The MANCOVA comparing executive function scores by treatment group revealed a
marginally significant treatment main effect (P = 0.078). Examination of the univariate
ANCOVA revealed a significant treatment main effect for Ruff total score (P = 0.01). Simple
contrasts revealed that exercisers had higher Ruff total scores compared with sertraline group
participants (P = 0.005). The simple contrast between exercisers and placebo group participants
was not significant. None of the other univariate tests comparing executive function scores by
treatment group were significant.
Neither the MANCOVA comparing memory scores by treatment group nor the MANCOVA
comparing verbal fluency/working memory scores by treatment group revealed significant
treatment main effects.
Optimal exercisers analyses—The three MANCOVA were repeated in which the top
tertile of exercisers (n = 27; average change in peak V̇O2 = 15.60%) were compared with all
participants receiving placebo (n = 35; average change in peak V̇O2 = −2.94%). The
MANCOVA comparing verbal fluency/working memory scores by treatment group revealed
a marginally significant treatment main effect (P = 0.06). Examination of the univariate
ANCOVA revealed a significant treatment main effect for animal naming (P = 0.04); exercisers
had higher posttreatment animal naming scores compared with placebo group participants.
None of the other univariate tests comparing verbal fluency/working memory scores by
treatment group were significant.
Neither the MANCOVA comparing memory scores by treatment group nor the MANCOVA
comparing executive function scores by treatment group revealed any significant treatment
main effects.
Post hoc analysis of age—Our sample was somewhat younger as compared with samples
from previous studies of exercise and neurocognitive function. Therefore, we decided to
examine the impact of participant age on our primary analyses in a series of post hoc analyses.
We observed that the inclusion of age as a covariate did not alter the results of our multivariate
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or univariate analyses. Also, we examined bivariate correlation coefficients between age and
change in individual neuropsychological test score (i.e., posttest minus pretest), and none were
found to be significant (P’s > 0.10). Finally, we performed a post hoc analysis in which our
primary analyses were repeated using a data set restricted to those participants who were older
than 55 yr (n = 38 exercise, 15 sertraline, and 15 placebo; sample age mean (SD) = 60 (5);
range, 55–81 yr). None of the MANCOVA were significant (P’s > 0.10).
Post hoc analysis of depression—Because our sample was clinically depressed, we
decided to examine the impact of participant depression on our primary analyses in a series of
post hoc analyses. We observed that the inclusion of change in depression as a covariate did
not alter the results of our multivariate or univariate analyses. Similarly, the inclusion of
depression severity as a covariate, assessed by either interview (HAM-D) or self-report (BDI),
did not alter the results of our multivariate or univariate analyses, regardless of whether
depression was measured at baseline or at posttest. Examination of bivariate correlation
coefficients revealed that reductions in depressive symptom severity were weakly associated
with improved neurocognitive performance and achieved statistical significance on only 2 of
11 tests (Ruff total, r = 0.16, P = 0.02; digit symbol, r = 0.15, P = 0.02). Finally, we performed
a post hoc analysis in which our primary analyses were repeated using a data set restricted to
those participants who were at least moderately depressed (HAM-D >17; n = 38 exercise, 18
sertraline, and 22 placebo; sample baseline HAM-D mean (SD) = 21.1 (2.8)). None of the
MANCOVA were significant (P’s > 0.10).
DISCUSSION
Surprisingly, we found little evidence to support the contention that aerobic exercise training
improves neurocognitive function in patients with MDD. We hypothesized that exercise
participants would have larger improvements in neuropsychological test performance
compared with patients receiving sertraline or placebo pill, especially on tests of executive
function. However, exercisers did not perform better on any of the neuropsychological
measures compared with placebo controls. Thus, our findings do not provide support for the
beneficial effects of exercise training on neurocognitive functioning.
That exercisers had higher executive function scores when compared with the sertraline group,
but not when compared with the placebo group, was an unexpected finding. Indeed, whereas
both exercisers and placebo controls appeared to improve on some tests of executive function
(i.e., Ruff 2 & 7 test and digit symbol), which could be attributed to practice effects or greater
familiarity with the test procedures, sertraline participants did not appear to improve on these
tests. Although sertraline has been associated with improved neurocognitive test performance
among depressed adults (18), some studies have reported that sertraline may be associated with
very mild neurocognitive decrements (27). In the present study, the higher executive function
test scores among participants in the exercise group compared with sertraline group participants
appears to be due to the lower performance among patients on sertraline rather than to
improvements in neurocognition resulting from exercise. Taken together, data from the present
study of patients with MDD do not provide support for an exercise-related improvement in
executive function nor in any other neurocognitive domain.
We observed a trend toward enhanced performance for exercise compared with placebo pill
in an exploratory analysis of optimal exercisers (i.e., exercisers in the top tertile of improvement
in aerobic fitness) on measures of verbal fluency in working memory. However, whereas
exercisers had higher scores on one test (i.e., animal naming) within this neurocognitive
domain, exercisers did not have higher scores on the other three tests within the same
neurocognitive domain (the placebo group actually had slightly higher mean scores) or on
neurocognitive tests from other domains. In the absence of a cogent explanation for
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improvement in animal naming, but not in other tests of generative naming or executive
function, we conclude that this finding is likely due to chance and is not considered meaningful.
The present findings appear to conflict with the conclusions of a recent meta-analysis (15),
which reported that aerobic fitness training interventions improve neurocognitive function of
older, sedentary adults by an average of 0.48 SD, “regardless of the type of cognitive task, the
training method, or participants’ characteristics” (p. 128). In that analysis, the reported effect
size for neurocognitive tests of executive function (0.68 SD for treatment groups vs
approximately 0.11 SD for control groups) was especially large. However, closer examination
of the 18 studies included in the meta-analysis suggests an inconsistent pattern of results, in
which we considered 5 to be positive (21,31,39,52,54), 6 equivocal (6,23,37,43,47,66), and 7
negative (14,22,30,34,41,45,50).1 Among the five positive studies, we considered one to have
limited generalizability because the clinical population studied had medical conditions that
would greatly impact their neuropsychological test performance (i.e., institutionalized
psychiatric patients (52)), whereas among the four remaining positive studies, only one used
a well-validated set of clinical neuropsychological instruments (21). Two of seven negative
studies (14,22) and two of six equivocal studies (23,37) also used well-validated
neuropsychological test batteries. Thus, our review of these 18 published exercise intervention
studies suggests that there is no consistent evidence supporting a relationship between
improved aerobic fitness and cognitive function.
Another recent meta-analysis of 37 studies by Etnier et al. (24) included eight randomized
controlled trials that were not included in the Colcombe and Kramer meta-analysis.
Examination of these eight studies suggests a similarly inconsistent pattern of findings, in
which we considered none to be positive, three to be equivocal (25,36,48), and five to be
negative (Russell, E. M., “unpublished manuscript/observations,” 1982; 8,12,65,68).2 Again,
our analysis suggests that there is no consistent evidence in the literature demonstrating a
relationship between improved aerobic fitness and cognitive function.
Although the present sample is generally younger than the samples included in the Colcombe
and Kramer meta-analysis, it is unlikely that the age of our sample accounted for the
discrepancy between our findings and the findings of Colcombe and Kramer. Although older
age is generally associated with lower scores on measures of neurocognitive function,
especially tests of fluid intelligence or executive functioning (40), there is little evidence that
age moderates the relationship between aerobic fitness and neurocognition either in our study
or in other published studies. For example, the recent meta-regression by Etnier et al. (24) did
not find evidence that age moderates a fitness–neurocognition relationship. Furthermore, the
Etnier et al. meta-analysis included four studies with samples that were similar to or younger
than those in the present study (8,12,36,68), none of which produced positive findings. Also,
with the exception of three studies (23,47,52), the studies included in the Colcombe and Kramer
meta-analysis enrolled healthy adults so that the presence of significant cognitive impairment
or sufficiently low neuropsychological test scores so as to produce a “floor effect” among these
participants was unlikely. Similarly, the present sample of depressed adults had
neuropsychological test scores that are well within ±1 SD of age, education, and/or gender-
corrected normative data. Thus, it is unlikely that age is to account for the discrepancy between
our negative findings and Colcombe and Kramer’s conclusions (15).
1“Positive” studies feature either a majority of positive findings for exercise among a minority of null findings or a pattern of positive
and null findings that were predicted a priori. “Negative” studies feature no positive findings for exercise. “Equivocal” studies have a
minority of positive findings for exercise among a majority of null findings. We considered (47) to be equivocal due to the absence of a
control group. A table detailing these findings can be found online at
http://www.duke.edu/web/behavioralmed/hoffman/HoffmanTable5.pdf.
2A table detailing these findings can be found online at http://www.duke.edu/web/behavioralmed/hoffman/HoffmanTable6.pdf.
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There is another recent meta-analysis of exercise and neurocognitive function (33). However,
this meta-analysis is exclusively focused on older adults with dementia or significant
neurocognitive impairment. Results of exercise interventions for individuals with such severe
neurocognitive deficits are unlikely to generalize to outpatient, healthy adults. Therefore,
studies from this meta-analysis were not considered relevant to the findings of our present
study.
Our failure to find an exercise-induced improvement in neurocognitive functioning in patients
with MDD raises questions about the robustness of the relationship of improved aerobic fitness
and enhanced neurocognition. Because it is difficult to compare results across studies in which
measures of neurocognitive function vary widely between studies, we recommend that
researchers adopt a core set of neuropsychological instruments in future studies and examine
the impact of exercise on neurocognition in both clinical and healthy populations.
Limitations
Findings from the present analysis should be interpreted with several limitations in mind. MDD
has been associated with suppressed neuropsychological test performance (28,40), and it is
possible that MDD obscured the impact of exercise on neurocognitive function in our sample.
However, a closer look at our sample suggests that the impact of MDD on neuropsychological
test scores likely was limited. Previous studies have shown that the relationship between MDD
and neurocognitive function is strongest when depression is severe (42), recurrent (46),
accompanied by psychotic features (57), inadequately treated (28), treatment resistant (67), or
has a late-life onset (53). However, our post hoc analyses suggested that depression did not
have a significant impact on neurocognitive functions in this study.
One possible explanation for weak relationship between depression and neurocognitive
function in our sample is that patients with MDD in the present study were not severely
depressed. The average participant in this study suffered from depression that was mild to
moderate in severity (the average HAM-D score was 17), nonrecurrent (58% had <2 prior
depressive episodes), early onset (i.e., before age 40), and generally responsive to treatment
(e.g., HAM-D scores declined by over 1 SD in each treatment group). In previous studies of
adults with uncomplicated, mild-to-moderate depression, the relationship between depression
severity and neurocognitive has been weak (1) and has not been consistently observed across
studies (3). Although we believe that the impact of MDD on neurocognitive test scores was
minimal, we nevertheless cannot rule out the possibility that depression affected our findings
and that the lack of exercise-related improvements in neurocognitive function many not
generalize to non-depressed patients.
It also is possible that the clinical neuropsychological instruments used in the present study
are not sufficiently sensitive to the specific effects of exercise on neurocognitive function.
Indeed, three of the five positive studies from the Colcombe and Kramer meta-analysis (31,
39,54) and one more recent study (16) observed positive effects for exercise primarily by using
computer-based flanker tests, which contrast simple and complex reaction time to assess
executive function. Although computer-based flanker tests have been used in research
laboratories and validated against brain imaging (16), they typically are not included in standard
neuropsychological test batteries (60) and were not used in the present study. It is uncertain
whether improvement on a flanker test, particularly in the setting of stable performance on
other measures of executive function, affects everyday memory, decision making, or quality
of life. We recommend further validation of this finding and future research examining its
relevance for daily living.
Another limitation of the present study is the relatively short duration of treatment. Although
4 months is sufficient to improve aerobic capacity and reduce depression (9,10), it may be too
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brief to impact neurocognitive functioning. Indeed, in two of the more noteworthy studies,
improved neurocognitive function was achieved in exercise intervention studies lasting 6
months (39) and 3 yr (54). Furthermore, the Colcombe and Kramer meta-analysis (15)
concluded that longer intervention periods are associated with increased effect sizes. Longer-
term studies of exercise and neurocognitive function may produce greater benefits.
The overall 6% improvement in aerobic capacity achieved by exercise participants in our study
is quite modest and may not have been sufficiently large to impact neurocognitive functioning.
However, Kramer et al. found positive effects for exercise on executive functioning with an
improvement in aerobic capacity of only 5.1% (39). Furthermore, a recent meta-analysis found
no association between change in aerobic fitness and neurocognitive function in intervention
studies (24), and we found little evidence of an exercise benefit even among our optimal
exercisers, who achieved >15% improvement in aerobic capacity. Although one interventional
study showed a dose–response relationship between aerobic exercise amount and changes in
depressive symptoms among clinically depressed adults (20), no randomized controlled trial
has tested the dose–response relationship between aerobic fitness and cognitive performance.
It is possible that aerobic exercise offers a neurocognitive benefit for people who suffer from
cognitive impairment. Indeed, a recent meta-analysis of exercise studies on people with
dementia and related cognitive impairment concluded that exercise was associated with
improved cognitive performance (33). Because participants in our sample were not cognitively
impaired, our null findings may not generalize to a cognitively impaired population.
SUMMARY
In summary, these findings suggest that exercise does not confer clinically meaningful
improvements in neurocognitive function among clinically depressed adults. Exercise offered
no clear benefit relative to placebo pill on any of the neuropsychological tests we used in this
study. Although exercise was associated with slightly better performance relative to sertraline
on a subset of tests, this could be attributed to sertraline-related decrement rather than exercise-
related improvement.
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TABLE 1
Factor loadings with individual tests.
Executive
Function
Verbal Fluency/
Working Memory
Verbal
Memory
Digit Symbol 80 40 19
Ruff Total 75 34 16
Stroop Color–Word 68 46 19
TMT B-A −72 −53 −23
Digits Backward 41 71 24
Digits Forward 29 62 11
COWAT 38 54 27
Animal Fluency 41 45 35
Verbal Paired Associates, hard 19 28 71
Verbal Paired Associates, easy 7 9 59
Logical Memory 21 23 52
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TABLE 3
Mean average treadmill test performance, by group and time.
Supervised
Exercise
(n = 51)
Home-Based
Exercise
(n = 53)
Sertraline
(n = 49)
Placebo
(n = 49)
Peak V ̇O2 (mL·min−1·kg−1)
  Before treatment 25.2 24.8 24.2 23.9
  After treatment 26.8 25.7 23.4 22.9
Treadmill test duration (s)
  Before treatment 620 591 562 575
  After treatment 704 634 558 562
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